This meeting will focus on the presentation of emerging data in basic, clinical, and epidemiologic research related to COVID-19 and cancer. COVID-19 has encouraged innovation by cancer investigators and physician-scientists to address this pandemic, including the development of new diagnostic assays and new virus-targeted drugs; testing of next-generation vaccines; repurposing of oncology drugs to treat...

Unite and Conquer: Accelerating Progress Together. A diverse program. A multidisciplinary perspective. A wealth of new research. The opportunities are limitless.

ANCO’s ASCO20 Virtual Highlights will summarize the major research and treatment advancements presented at this year’s ASCO20 Virtual Meeting. The program will focus on breast, gastrointestinal, genitourinary, head and neck, and lung cancers as well as a panel on cancer care during the time of COVID-19. The faculty will place these developments in context as...

The ASH Meeting on Hematologic Malignancies has transitioned to a virtual setting in their efforts to keep attendees, presenters, and ASH staff safe in the midst of the coronavirus pandemic.They are committed to continuing our work with you, our global network of researchers and clinicians, to better understand, prevent, and treat blood disorders, and we...

The faculty will present the latest research on treatment modalities for hematologic malignancies—leukemias, lymphomas, and myeloma—along with case studies for these diagnoses. The program takes place virtually on: • September 12th with Case Presentations from UC Davis, and• November 14th with Case Presentations from UC San Francisco • December 19th with Case Presentations from Stanford...

This activity has been planned for clinicians who treat lung cancer patients: knowing how COVID-19 alters physiology is crucial to providing care that will ameliorate infection symptoms while not exacerbating lung cancer symptoms. Further, clinicians must be aware of factors that increase these patients' risk for COVID-19 infection, including decreased immunity due to pharmacotherapy and...

The 2020 ASCO Quality Care Symposium will include a robust scientific and educational program, and abstracts accepted to the meeting will be presented virtually and published in a supplement to the Journal of Clinical Oncology. With the virtual symposium, we aim to bring together a collaborative cohort of research, science, and recommendations focused on quality...

The use of targeted intra-operative radiotherapy (TARGIT), as a single dose – with ZEISS INTRABEAM – directly after removal of a tumor, is confirmed as non-inferior, when compared with external beam radiotherapy (EBRT). The TARGIT-A study further is the largest international multicenter study with a follow-up time of 8.6 years. In addition to its effectiveness,...

This activity has been planned for clinicians who treat lung cancer patients: knowing how COVID-19 alters physiology is crucial to providing care that will ameliorate infection symptoms while not exacerbating lung cancer symptoms. Further, clinicians must be aware of factors that increase these patients' risk for COVID-19 infection, including decreased immunity due to pharmacotherapy and...

Cancer treatments are advancing at an astounding pace, with newer therapies providing better outcomes, longer life, and greater chance for cure. Radiation therapy plays an essential role in the treatment of many cancers and innovations in radiation treatments have similarly lead to improved outcomes in both survival and quality of life. In this course, participants...